ABT-493/ABT-530

DRUG10 trials

Sponsors

AbbVie

Conditions

Chronic Hepatitis CChronic Hepatitis C VirusChronic Hepatitis C Virus (HCV) InfectionCompensated CirrhosisDirect-Acting Antiviral Agent (DAA)-ExperiencedGenotype 3 Hepatitis C VirusHCVHepatitis C Virus

Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

CompletedNCT02243293

AbbVieChronic Hepatitis C, Hepatitis C Virus

Start: 2014-09-19End: 2017-02-23Updated: 2021-07-30

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

CompletedNCT02446717

AbbVieChronic Hepatitis C, Direct-Acting Antiviral Agent (DAA)-Experienced, HCV +1

Start: 2015-04-30End: 2017-01-31Updated: 2017-09-15

Phase 3

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

CompletedNCT02604017

AbbVieChronic Hepatitis C, HCV, Hepatitis C Virus

Start: 2015-10-31End: 2017-01-31Updated: 2021-07-13

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

CompletedNCT02636595

AbbVieHepatitis C Virus

Start: 2015-11-30End: 2017-01-31Updated: 2021-07-13

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

CompletedNCT02640157

AbbVieChronic Hepatitis C, Genotype 3 Hepatitis C Virus, Hepatitis C Virus

Start: 2015-12-31End: 2017-02-28Updated: 2021-07-30

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

CompletedNCT02640482

AbbVieChronic Hepatitis C Virus (HCV) Infection

Start: 2015-11-30End: 2017-02-28Updated: 2021-07-16

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

CompletedNCT02642432

AbbVieChronic Hepatitis C, Compensated Cirrhosis, Hepatitis C Virus Infection

Start: 2015-12-07End: 2017-02-10Updated: 2021-07-13

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection

CompletedNCT02651194

AbbVieChronic Hepatitis C Virus (HCV) Infection

Start: 2015-12-31End: 2017-01-31Updated: 2017-10-16

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection

CompletedNCT02707952

AbbVieChronic Hepatitis C Virus, Hepatitis C Virus

Start: 2016-02-22End: 2017-02-09Updated: 2021-07-16

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

CompletedNCT02723084

AbbVieChronic Hepatitis C Virus, Hepatitis C Virus

Start: 2016-04-08End: 2017-03-24Updated: 2021-07-16

Related Papers

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension

Infectious Diseases and Therapy2022-02-173 citations

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials

Liver International2019-10-0131 citations

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection

Journal of Gastroenterology2019-03-1319 citations

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

Clinical Infectious Diseases2019-01-2336 citations

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.

2018-09-1015 citations

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

New England Journal of Medicine2018-01-25426 citations

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

Antimicrobial Agents and Chemotherapy2017-11-2749 citations

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

New England Journal of Medicine2017-10-11394 citations

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

2017-09-22154 citations

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

2017-08-14232 citations

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

2017-04-13213 citations

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.

2016-07-2573 citations